SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 27, 2015
(Exact name of registrant as specified in its charter)
(State or other
235 East 42nd Street
New York, New York
(Address of principal executive offices)
Registrant's telephone number, including area code:
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On January 27, 2015, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth-quarter and full-year 2014. The information contained in the press release is deemed to be “filed” under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
Exhibit 99 -
Press Release of Pfizer Inc. dated January 27, 2015, reporting
Pfizer's financial results for the fourth-quarter and full-year 2014. Exhibit 99
is deemed to be “filed” under the Securities Exchange Act of 1934
in this Current Report on Form 8-K.
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
/s/ Atiba D. Adams
Atiba D. Adams
Vice President and Corporate Secretary
Dated: January 27, 2015
Press Release of Pfizer Inc. dated
January 27, 2015, reporting Pfizer's financial
results for the fourth-quarter and full-year 2014.